Breast Cancer Canada and AstraZeneca Canada Advance Next-Generation Survivorship Research

Skip to Content News Archives Economy Defence Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Defence Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Defence Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeBusiness Wire News ReleasesPMN Press ReleasesThis section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Breast Cancer Canada and AstraZeneca Canada Advance Next-Generation Survivorship ResearchAuthor of the article:Kimberly Carson and Dave Finlay announce grant award winners. Business WireAnnounced at ESMO 2026: $200,000 in matched funding to advance the future of Canadian breast cancer survivorship.THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountTORONTO — Breast Cancer Canada and AstraZeneca Canada are investing $200,000 in matched research funding to address critical gaps in breast cancer survivorship and improve care for Canadians living with and beyond the disease. Announced at Breast Cancer Canada’s Canadian Night reception during the European Society for Medical Oncology (ESMO) Congress in Madrid, the funding will support two Canadian research initiatives, each receiving $100,000 to advance innovative approaches to patient navigation, survivorship research and personalized care.This advertisement has not loaded yet, but your article continues below.Through this partnership, Breast Cancer Canada and AstraZeneca Canada are advancing research and innovation to address critical gaps across the survivorship continuum. The funded projects will explore digital health and artificial intelligence (AI) approaches to strengthen patient navigation, better understand patient needs, and inform more coordinated, personalized care.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againThe announcement comes as survey data from Breast Cancer Canada highlights public support for better survivorship care:92% of Canadians agree the cancer journey does not end when active treatment concludes.83% support medically supervised survivorship plans to guide patients through long-term recovery.“Finishing active treatment is a major milestone, but it is not the end of a patient’s breast cancer journey,” said Kimberly Carson, CEO of Breast Cancer Canada. “Patients can face ongoing side effects, uncertainty, and complex medical decisions for years. Through our partnership with AstraZeneca Canada, we are investing in responsible innovation to help ensure survivorship care advances alongside precision treatment.”“At AstraZeneca, we’re driven by a bold ambition: to eliminate cancer as a cause of death, and that ambition extends beyond treatment to ensuring every survivor has access to the care and innovation they need to thrive,” said Dave Finlay, Franchise Head, Breast Cancer at AstraZeneca Canada. “We are proud to partner with Breast Cancer Canada to support Dr. Kamal Haider and Dr. Amina Silva, whose research aims to improve care coordination, strengthen support and advance more personalized approaches to survivorship.”Breast Cancer Canada and AstraZeneca Canada Matched Research Grant RecipientsPatient Navigation After Treatment and Digital Health ($100,000)Led by Dr. Kamal Haider, Medical Oncologist at the University of Saskatchewan, the SAGE-S project will explore and validate a two-way large language model to support survivorship, with research coordination across Saskatchewan, Alberta and British Columbia.After active treatment, patients may continue taking long-term medications and managing side effects. Between appointments, accessing reliable information and knowing how to respond to changing symptoms can be challenging.SAGE-S will investigate whether a secure, clinician-supported AI tool can provide tailored education and symptom-management support between visits. The project will assess how digital health technology can complement clinical care.This advertisement has not loaded yet, but your article continues below.Long-Term Resource Framework for Metastatic Breast Cancer ($100,000)Led by Dr. Amina Silva, PhD, RN, at Brock University in Ontario, this project will examine the ongoing needs of people living with metastatic breast cancer to inform more responsive, coordinated care.People living with metastatic breast cancer often experience ongoing physical, emotional, and financial challenges while navigating ongoing treatment across multiple specialists and healthcare settings. As their circumstances change, ensuring care reflects their priorities can be difficult.Using AI-assisted analysis of experiences shared in online support groups, the project will identify unmet needs and develop a practical framework for nursing support. The findings will help inform more personalized approaches to care that better reflect the experiences and priorities of people living with metastatic breast cancer.Advancing Survivorship for Canadians Affected by Breast CancerSurvivorship is a core pillar of Breast Cancer Canada’s national advocacy and education strategy, reflecting the need for care that extends beyond active treatment. Canadians living with and beyond breast cancer may experience lasting physical, emotional, cognitive, sexual and financial impacts, alongside ongoing monitoring and follow-up needs that are not consistently addressed across the healthcare system.The investment with AstraZeneca Canada advances this commitment by supporting research into practical, patient-centred approaches to survivorship care. From exploring AI-enabled tools to improve access to information and symptom-management support to identifying the evolving needs of people living with metastatic breast cancer, the two projects aim to generate insights that can inform more coordinated, personalized care.“Canada possesses world-class research and clinical expertise,” added Carson. “This joint funding supports research designed to translate findings into practical, accessible support for Canadians living beyond breast cancer. By investing in survivorship research and innovation, we can build a stronger understanding of patients’ needs and advance more coordinated, patient-centred care.”About Breast Cancer CanadaBreast Cancer Canada is a national charity dedicated to funding breast cancer research to improve outcomes for Canadians affected by the disease. Through research, education and advocacy, Breast Cancer Canada works to advance precision oncology, improve access to evidence-based care and address gaps across the breast cancer care continuum. Learn more at breastcancer.caView source version on businesswire.com: This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.